The content is available as a PDF (266.2 KB).
Bibliografía
- 1.McCarthy D. Nonsteroidal anti-inflammatory drug-related gastrointestinal toxicity: Definitions and epidemiology. Am J Med. 1998;105:3–9. doi: 10.1016/s0002-9343(98)00274-5. [DOI] [PubMed] [Google Scholar]
- 2.Hernández Díaz S., García Rodríguez L.A. Association between nonsteroidal antiinflammatory drugs and upper gastrointestinal tract bleeding/perforation. Arch Intern Med. 2000;160:2093–2099. doi: 10.1001/archinte.160.14.2093. [DOI] [PubMed] [Google Scholar]
- 3.Yeomans N.D., Tulassay Z., Juhász L., Rácz I., Howard J., Van Rensburg C.J. A comparison of omeprazole with ranitidine for ulcers associated with nonsteroidal antiinflammatory drugs. N Engl J Med. 1998;338:719–726. doi: 10.1056/NEJM199803123381104. [DOI] [PubMed] [Google Scholar]
- 4.Hawkey C.J., Karrasch J.A., Szczepañski L., Walker D.G., Barkun A., Swannell A.J. Omeprazole compared with misoprostol for ulcers associated with nonsteroidal antiinflammatory drugs. N Engl J Med. 1998;338:727–734. doi: 10.1056/NEJM199803123381105. [DOI] [PubMed] [Google Scholar]
- 5.Day R., Morrison B., Luza A., Castaneda O., Strusberg A., Nahir M. A randomized trial of the efficacy and tolerability of the COX-2 inhibitor rofecoxib vs ibuprofen in patients with osteoarthritis. Arch Intern Med. 2000;160:1781–1787. doi: 10.1001/archinte.160.12.1781. [DOI] [PubMed] [Google Scholar]
- 6.Saag K., Van der Heijde D., Fisher C., Samara A., De Tora L., Bolognese J. Rofecoxib, a new cyclooxygenase 2 inhibitor, shows sustained efficacy, comparable with other nonsteroidal anti-inflammatory drugs. Arch Fam Med. 2000;9:1124–1134. doi: 10.1001/archfami.9.10.1124. [DOI] [PubMed] [Google Scholar]
- 7.Bombardier C., Laine L., Reicin A., Shapiro D., Burgos-Vargas R., Davis B. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. N Engla J Med. 2000;343:1520–1528. doi: 10.1056/NEJM200011233432103. [DOI] [PubMed] [Google Scholar]
- 8.Bensen W., Fiechtner J., McMillen J., Zhao W., Yu S., Woods E. Treatment of osteoarthritis with celecoxib, a cyclooxygenase-2 inhibitor: a randomized controlled trial. Mayo Clin Proc. 1999;74:1095–1105. doi: 10.4065/74.11.1095. [DOI] [PubMed] [Google Scholar]
- 9.Simon L.S., Weaver A.L., Graham D.Y., Kivitz A.J., Lipsky P.E., Hubbard R.C. Anti-inflammatory and upper gastrointestinal effects of celecoxib in rheumatoid arthritis: a randomized controlled trial. JAMA. 1999;282:1921–1928. doi: 10.1001/jama.282.20.1921. [DOI] [PubMed] [Google Scholar]
- 10.Emery P., Zeidler H., Kvien T., Guslandi M., Naudin R., Stead H. Celecoxib versus diclofenac in long-term management of rheumatoid arthritis: a randomised double blind comparison. Lancet. 1999;354:2106–2111. doi: 10.1016/S0140-6736(99)02332-6. [DOI] [PubMed] [Google Scholar]
- 11.Langman M.J., Jensen D., Watson D.J., Harper S.E., Zhao P.L., Quan H. Adverse upper gastrointestinal effects of rofecoxib compared with NSAIDs. JAMA. 1999;282:1929–1933. doi: 10.1001/jama.282.20.1929. [DOI] [PubMed] [Google Scholar]
- 12.Goldstein J.L., Silverstein F.E., Agrawal N.M., Hubbard R.C., Kaiser J., Maurath C.J. Reduced risk of upper gastrointestinal ulcer complications with celecoxib, a novel COX-2 inhibitor. Am J Gastroenterol. 2000;95:1681–1690. doi: 10.1111/j.1572-0241.2000.02194.x. [DOI] [PubMed] [Google Scholar]
- 13.Silverstein F.E., Faich G., Goldstein J.L., Simon L.S., Pincus T., Whelton A. Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid artritis. The CLASS study: a randomized controlled trial. JAMA. 2000;284:1247–1255. doi: 10.1001/jama.284.10.1247. [DOI] [PubMed] [Google Scholar]
- 14.Whelton A., Maurath C.J., Verburg K.M., Geis G.S. Renal safety and tolerability of celecoxib, a novel cyclooxygenase-2-inhibitor. Am J Therap. 2000;7:159–175. doi: 10.1097/00045391-200007030-00004. [DOI] [PubMed] [Google Scholar]
- 15.Whelton A., Fort J.G., Puma J.A., Normandin D., Bello A.E., Verburg K.M. Cyclooxygenase-2-specific inhibitors and cardiorenal function: a randomized, controlled trial of celecoxib and rofecoxib in older hypertensive osteoarthritis patients. Am J Therap. 2001;8:85–95. doi: 10.1097/00045391-200103000-00003. [DOI] [PubMed] [Google Scholar]
- 16.Mukherjee D., Nissen S.E., Topol E.J. Risk of cardiovascular events associated with selective COX-2 inhibitors. JAMA. 2001;286:954–959. doi: 10.1001/jama.286.8.954. [DOI] [PubMed] [Google Scholar]